References
- Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region: epidemiologic study in central Bohemia. Chest 1993;104:1486-9. https://doi.org/10.1378/chest.104.5.1486
- Daniil ZD, Zintzaras E, Kiropoulos T, Papaioannou AI, Koutsokera A, Kastanis A, et al. Discrimination of exudative pleural effusions based on multiple biological parameters. Eur Respir J 2007;30:957-64. https://doi.org/10.1183/09031936.00126306
- Light RW. Clinical practice: pleural effusion. N Engl J Med 2002;346:1971-7. https://doi.org/10.1056/NEJMcp010731
- Hooper C, Lee YC, Maskell N; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65 Suppl 2:114-17.
- Yilmaz Turay U, Yildirim Z, Turkoz Y, Biber C, Erdogan Y, Keyf AI, et al. Use of pleural fluid C-reactive protein in diagnosis of pleural effusions. Respir Med 2000;94:432-5. https://doi.org/10.1053/rmed.1999.0759
- Kiropoulos TS, Kostikas K, Oikonomidi S, Tsilioni I, Nikoulis D, Germenis A, et al. Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respir Med 2007;101:910-8. https://doi.org/10.1016/j.rmed.2006.09.019
- Lin MC, Chen YC, Wu JT, Ko YC, Wang CC. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 2009;136:205-11. https://doi.org/10.1378/chest.08-1134
- Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-Gonzalez A, Martinez- Iribarren A, et al. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 2009;34:1383-9. https://doi.org/10.1183/09031936.00197208
- Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41. https://doi.org/10.1161/01.CIR.102.6.636
- He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol 2007;292:L1039-49. https://doi.org/10.1152/ajplung.00490.2006
- Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in antifungal innate immune response. Nature 2002;420:182-6. https://doi.org/10.1038/nature01195
- Ozsu S, Abul Y, Mentese A, Bektas H, Uzun A, Ozlu T, et al. Pentraxin-3: a novel biomarker for discriminating parapneumonic from other exudative effusions. Respirology 2013;18:657-62. https://doi.org/10.1111/resp.12038
- Papageorgiou E, Kostikas K, Kiropoulos T, Karetsi E, Mpatavanis G, Gourgoulianis KI. Increased oxidative stress in exudative pleural effusions: a new marker for the differentiation between exudates and transudates? Chest 2005;128:3291-7. https://doi.org/10.1378/chest.128.5.3291
- Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13. https://doi.org/10.7326/0003-4819-77-4-507
- Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66. https://doi.org/10.1146/annurev.immunol.23.021704.115756
- Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. https://doi.org/10.1056/NEJM199902113400607
- Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008;36:2302-8. https://doi.org/10.1097/CCM.0b013e3181809aaf
- He X, Han B, Bai X, Zhang Y, Cypel M, Mura M, et al. PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med 2010;36:356-64. https://doi.org/10.1007/s00134-009-1720-0
- Porcel JM, Bielsa S, Esquerda A, Ruiz-Gonzalez A, Falguera M. Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. Eur J Intern Med 2012;23:447-50. https://doi.org/10.1016/j.ejim.2012.03.002
- Chen SC, Chen W, Hsu WH, Yu YH, Shih CM. Role of pleural fluid C-reactive protein concentration in discriminating uncomplicated parapneumonic pleural effusions from complicated parapneumonic effusion and empyema. Lung 2006;184:141-5. https://doi.org/10.1007/s00408-005-2573-0
- Chierakul N, Kanitsap A, Chaiprasert A, Viriyataveekul R. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion. Respirology 2004;9:66-9. https://doi.org/10.1111/j.1440-1843.2003.00521.x
Cited by
- Pentraxin 3 as a Prognostic Biomarker in Patients with Systemic Inflammation or Infection vol.2014, pp.None, 2013, https://doi.org/10.1155/2014/421429
- Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study vol.18, pp.5, 2013, https://doi.org/10.1186/s13054-014-0562-5
- Performance of procalcitonin in diagnosing parapneumonic pleural effusions: A clinical study and meta-analysis vol.96, pp.33, 2017, https://doi.org/10.1097/md.0000000000007829
- Efficacy of procalcitonin and pentraxin-3 as early biomarkers for differential diagnosis of pleural effusions vol.6, pp.2, 2013, https://doi.org/10.1515/pp-2021-0111